Abstracts tagged "Bioinformatics"

Abstract Number: 1406 • ACR Convergence 2022
Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis
Benjamin Hur¹, Kevin Cunningham², John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²University of Minnesota, Rochester, MN
Background/Purpose: ACPA detection assays are often used for RA diagnosis due to their high specificity ( >90%). However, current ACPA assays (e.g., anti-CCP2 ELISA) have…
Abstract Number: 0501 • ACR Convergence 2022
Single-molecule Spatial Transcriptomic Analysis Reveals Distinct Cellular Networks in Rheumatoid Arthritis Synovia
Roopa Madhu¹, Kartik Bhamidipati¹, Nghia Millard², Michelle Curtis², Ye Cui³, Youngmi Kim³, Ellen Gravallese⁴, Soumya Raychaudhuri¹, Michael Brenner⁴, ilya Korsunsky¹ and Kevin Wei⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Boston, MA, ³Nanostring Technologies Inc., Seattle, WA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic joint inflammation in rheumatoid arthritis (RA) arises from the interactions of many cell types. Single-cell transcriptomic profiling of RA joints has identified novel…
Abstract Number: 1110 • ACR Convergence 2022
Solving Sarcoidosis: A Transcriptome-based Meta-analysis of Clinical Sarcoidosis Studies Illustrates Shared Pathophysiology, Identifies Candidate Biomarkers and Suggests a Therapeutic Mechanism of JAK Inhibition
Ingrid Lindquist¹, James T. Rosenbaum² and Marcia Friedman³, ¹Oregon Health and Science University, Portland, OR, ²Legacy Devers Eye Institute, Portland, OR, ³Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR
Background/Purpose: Sarcoidosis is a systemic, non-caseating granulomatous disease driven by a dysregulated immune response to environmental antigens. A wide range of clinical manifestations coupled with…
Abstract Number: 1415 • ACR Convergence 2022
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Mona Alotaibi¹, Roxana Coras², Dimitrios Pappas³, Ted Mikuls⁴, Joel Kremer⁵, Geoffrey Thiele⁶, mohit jain¹ and Monica Guma⁷, ¹Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³CorEvitas, LLC, Waltham, MA, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷UCSD, La Jolla, CA
Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier…
Abstract Number: 0519 • ACR Convergence 2022
Myeloablation Followed by Hematopoietic Stem Cell Transplantation Leads to Long-term Normalization of Systemic Sclerosis Molecular Signatures
Nancy Wareing¹, Xuan Wang², Lynette Keyes-Elstein³, Ellen Goldmuntz⁴, Marka Lyons⁵, Peter McSweeney⁶, Daniel Furst⁷, Richard Nash⁶, Leslie Crofford⁸, Beverly Welch⁹, Ashley Pinckney¹⁰, Maureen Mayes¹¹, Keith Sullivan¹² and Shervin Assassi¹³, ¹UTHealth Houston McGovern Medical School, Houston, TX, ²Baylor Institute for Immunology Research, Dallas, TX, ³Rho, Chapel Hill, NC, ⁴NIAID/ NIH, Washington, DC, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Colorado Blood Cancer Institute, Denver, CO, ⁷University of California Los Angeles, Los Angeles, CA, ⁸Vanderbilt University Medical Center, Nashville, TN, ⁹NIAID/NIH, Bethesda, MD, ¹⁰Rho, St. Louis Park, MN, ¹¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ¹²Duke University, Durham, NC, ¹³McGovern Medical School, University of Texas, Houston, TX
Background/Purpose: In the randomized Scleroderma: Cyclophosphamide Or Transplantation (SCOT trial), normalization of systemic sclerosis (SSc) peripheral blood gene expression signatures at the 26-month visit was…
Abstract Number: 1114 • ACR Convergence 2022
Computational Drug Repositioning and 3D Skin Models Identify EGFR and PI3K Inhibitors as Anti-fibrotic Targets for Systemic Sclerosis
Dillon Popovich¹, Noelle Kosarek², Rezvan Parvizi³, Tamar Abel⁴, Mengqi Huang⁵, Monica Espinoza⁶, Avi Smith⁷, Sasha Shenk⁷, Jonathan Garlick⁷ and Michael Whitfield⁸, ¹Dartmouth College, West Lebanon, NH, ²Dartmouth Geisel School of Medicine, Lebanon, NH, ³Dartmouth, Lebanon, NH, ⁴Dartmouth College, Lebanon, NH, ⁵University of Pittsburgh, Pittsburgh, PN, ⁶Dartmouth College, Hanover, NH, ⁷Tufts University School of Dental Medicine, Boston, MA, ⁸Geisel School of Medicine, Lebanon, NH
Background/Purpose: Genome-wide analyses of gene expression in systemic sclerosis (SSc) skin biopsies have identified differential responses based on the mechanism of action of the therapy.…
Abstract Number: 1428 • ACR Convergence 2022
Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab
Daniel Toro-Domínguez¹, José Linares-Blanco¹, Raúl López-Domínguez², Pilar S. López-Garrido², Georgina Galicia-Rosas¹, Pedro Carmona-Sáez² and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²University of Granada, Granada, Spain
Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent rheumatic diseases, mainly characterized by chronically painful, swollen joints that can severely impair physical function…
Abstract Number: 0536 • ACR Convergence 2022
Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Andrea Fava¹, Laurence S Magder², Daniel W. Goldman³, Jill Buyon⁴, Betty Diamond⁵, Joel Guthridge⁶, William Apruzzese⁷, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter Izmirly⁴, H Michael Belmont⁸, Anne Davidson⁵, Maria Dall'Era⁹, Deepak Rao⁷, Arnon Arazi¹⁰, Nir Hacohen¹¹, Soumya Raychaudhuri⁷, the Accelerating Medicines Partnership (AMP) RA/SLE¹² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Brigham and Women's Hospital, Boston, MA, ⁸NYU School of Medicine, New York, NY, ⁹University of California, San Francisco, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Melrose, MA, ¹¹Broad Institute, Cambridge, MA, ¹²Multiple Insitutions
Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
Abstract Number: 1118 • ACR Convergence 2022
Monocyte Transcriptomic Analysis Uncovers Heterogeneous Gene Expression Profiles in Systemic Lupus Erythematous (SLE) with and Without Subclinical Atherosclerosis
Laurel Woodridge¹, Elvira Chocano Navarro², George Robinson¹, Paul Ashford¹, Kirsty Waddington³, Anisur Rahman⁴, Christine Orengo⁵, Ines Pineda-Torra⁶ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²VIHR, Barcelona, Spain, ³University College London (alumni), London, United Kingdom, ⁴Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵ISMB / UCL, London, United Kingdom, ⁶Cabimer, Sevilla, Spain
Background/Purpose: A leading cause of mortality in SLE is cardiovascular disease (CVD) through accelerated atherosclerosis: the build-up of cells and lipids in the vascular wall.…
Abstract Number: 1473 • ACR Convergence 2022
Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
Jack Zent¹, Kristy Bell², Brooke Williams², Prathyusha Bachali³ and Peter Lipsky⁴, ¹AMPEL BioSolutions LLC, Leesburg, VA, ²AMPEL BioSolutions LLC, Charlottesville, VA, ³AMPEL BioSolutions, Redmond, WA, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical presentations. Patient-reported outcomes (PROs) can aid in the measurement of the burden of…
Abstract Number: 0554 • ACR Convergence 2022
Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Clinical Onset
Megan Hanlon¹, Mary Canavan², conor Smith³, Achilleas Floudas⁴, Nuno Neto⁵, Qingxuan Song⁶, Phil Gallagher⁷, Ronan Mullan⁸, Conor Hurson⁹, Barry Moran⁵, Michael Monaghan⁵, Sunil Nagpal¹⁰, Douglas Veale¹¹ and Ursula Fearon⁵, ¹Molecular Rheumatology, Dublin, Ireland, ²Trinity College, Dublin, Ireland, ³bTrinity College Dublin, Dublin, Ireland, ⁴Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁵Trinity College Dublin, Dublin, Ireland, ⁶Janssen Research and Development, LLC, Spring House, PA, ⁷St Vincent's University Hospital, Dublin, Ireland, ⁸Tallaght University Hospital, Dublin, Ireland, ⁹St Vincents University Hospital, Dublin, Ireland, ¹⁰Janssen Research, Collegeville, PA, ¹¹St. Vincent's University Hospital, Blackrock, Dublin, Ireland
Background/Purpose: Synovial-tissue macrophages significantly contribute to Rheumatoid Arthritis, yet the precise nature/function of macrophage subsets within the inflamed joint remains unexplored. Here we explore the…
Abstract Number: 1119 • ACR Convergence 2022
Investigating Macrophage Heterogeneity in the Esophagus and Lungs of SSc Patients
Hadijat Makinde¹, Carla Cuda¹, Miranda Gurra¹, Mary Carns², Kathleen Aren², Gaurav Gadhvi¹, Salina Dominguez¹, Jane Dematte³, Darren Brenner⁴, John Pandolfino⁵, G. R. Scott Budinger⁴, Deborah Winter⁶ and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University Division of Rheumatology, Chicago, IL, ³Northwestern University, Elmhurst, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Feinberg School of Medicine, Wilmette, IL, ⁶Northwestern University, Skokie, IL
Background/Purpose: Our group has made important contributions to an emerging understanding of monocytes and macrophages as central to SSc pathogenesis. There are numerous studies that…
Abstract Number: 1607 • ACR Convergence 2022
Machine Learning Identifies Biomarker of Non-Response to Methotrexate in Rheumatoid Arthritis
Vincent Bouget¹, Julien Duquesne¹, Paul-Henry Cournède², Bruno Fautrel³, Francis Guillemin⁴, Pascal de Jong⁵, Judith Heutz⁶, Marloes Verstappen⁷, Annette van der Helm-van Mil⁸, Xavier Mariette⁹ and Samuel Bitoun¹⁰, ¹Scienta Lab, Paris, France, ²Paris-Saclay University - CentraleSupelec, Paris, France, ³Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁴Université de Lorraine, APEMAC, Vandoeuvre-les-nancy, France, ⁵ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁶Erasmus Medical Center, Rotterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, ⁹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁰Paris-Saclay University, Paris, France
Background/Purpose: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA). Unfortunately, 30% to 40% of RA patients do not respond to MTX with…
Abstract Number: 0564 • ACR Convergence 2022
Identifying Shared Genetic Architecture Between RA and Other Conditions: A Phenome-Wide Association Study
Harrison Zhang¹, Gregory McDermott², Thany Seyok², Sicong Huang², Kumar Dahal², Sehi L'Yi¹, Clara Lea-Bonzel¹, Jacklyn Stratton², Dana Weisenfeld², Tianrun Cai², Paul Monach³, Jing Cui², Chuan Hong⁴, Tianxi Cai⁵ and Katherine Liao², ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³VA Boston Healthcare System, Boston, MA, ⁴Duke University, Durham, NC, ⁵Harvard TH Chan School of Public Health, Boston, MA
Background/Purpose: RA shares individual risk alleles with other autoimmune conditions such as type 1 diabetes and celiac disease. However, there are limited studies examining the…
Abstract Number: 1120 • ACR Convergence 2022
Transcriptome-Wide Association Study of Sjögren’s Disease Risk Alleles Identifies Novel Genes with Altered Expression in Minor Salivary Gland and Other Tissues
Marcin Radziszewski¹, Mandi Wiley¹, Bhuwan Khatri¹, Kandice Tessneer¹, Astrid Rasmussen¹, Professor Simon Bowman², Lida Radfar³, Roald Omdal⁴, Marie Wahren-Herlenius⁵, Blake Warner⁶, Torsten Witte⁷, Roland Jonsson⁸, Maureen Rischmueller⁹, Patrick Gaffney¹, Judith James¹, Lars Ronnblom¹⁰, R. Hal Scofield³, Xavier Mariette¹¹, Marta Alarcon-Riquelme¹², Fai Ng¹³, Gunnel Nordmark¹⁰, Umesh Deshmukh¹, A. Darise Farris¹ and Christopher Lessard¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University Hospitals Birmingham, Birmingham, United Kingdom, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Stavanger University, Stavanger, Norway, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Institutes of Health, Bethesda, MD, ⁷MH-Hannover, Hannover, Germany, ⁸University of Bergen, Bergen, Norway, ⁹RheumatologySA, Adelaide, Australia, ¹⁰Uppsala University, Uppsala, Sweden, ¹¹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹³Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease characterized by reduced function of exocrine glands, but also has systemic manifestations affecting multiple organs, including abnormal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].